What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?
If a patient has already received ADT+ARSI would you use PARPi over chemotherapy in 2nd line?
Community PollStarted
What is your preferred next line of treatment for patients with BRCA+/HRR mutated mCRPC progressing on first line ADT + ARSI?
48 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · The University of Texas Health Science Center at San Antonio
Answered on
We have data that chemotherapy is generally superior to next-line ARSI. However, we are still lacking definitive data on sequencing chemotherapy and PARPi. Based on my clinical experience and what can try to learn from studies regarding the toxicities of chemotherapy and PARPi, I believe that PARPi ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on
Based on the available data, to most accurately answer this difficult question of “What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC, after progression on first line combinations?” I would first separate it into two groups, BRCA+/mCRPC and HRR+/mCRPC, and choose my...
Join for free or sign in to see the full answer